CANIDIAP; CANagliflozin In DIAlysis Patients

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522742-46-00

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney disease

Brief summary

The overall percentage of receptor occupancy.

Detailed description

The percentage of receptor occupancy in the specific regions of interest., The overall percentage of receptor occupancy compared between dialysis patients that have and that do not have residual diuresis.

Interventions

DRUG18F-Canagliflozin

DRUGInvokana 300 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The overall percentage of receptor occupancy.	—

Secondary

Measure	Time frame
The percentage of receptor occupancy in the specific regions of interest., The overall percentage of receptor occupancy compared between dialysis patients that have and that do not have residual diuresis.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 24, 2026